Holen Sie sich die Stockscreener-App
190.57
6.32%
-12.85
Handel nachbörslich:
190.43
-0.14
-0.07%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RMD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$203.42
Offen:
$203.75
24-Stunden-Volumen:
3.52M
Relative Volume:
2.90
Marktkapitalisierung:
$27.64B
Einnahmen:
$5.54B
Nettoeinkommen (Verlust:
$1.52B
KGV:
18.37
EPS:
10.3734
Netto-Cashflow:
$1.74B
1W Leistung:
-8.40%
1M Leistung:
-10.08%
6M Leistung:
-25.51%
1J Leistung:
-22.25%
1-Tages-Spanne:
$190.38
$205.09
1-Wochen-Bereich:
$190.38
$211.56
52-Wochen-Spanne:
$190.38
$293.81
Resmed Inc Stock (RMD) Company Profile
Firmenname
Resmed Inc
Sektor
Telefon
(858) 746-2400
Adresse
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
190.57 | 29.51B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
424.64 | 150.03B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
147.12 | 40.89B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
66.29 | 32.02B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
36.56 | 31.12B | 29.14B | 1.07B | 1.05B | 1.1956 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | JP Morgan | Overweight |
| 2025-12-16 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | Eingeleitet | Citigroup | Buy |
| 2025-09-02 | Hochstufung | CLSA | Hold → Outperform |
| 2025-07-15 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-01-16 | Eingeleitet | Goldman | Buy |
| 2025-01-10 | Eingeleitet | Piper Sandler | Neutral |
| 2024-12-13 | Eingeleitet | Stifel | Hold |
| 2024-09-24 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-09-18 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Herabstufung | Needham | Buy → Hold |
| 2024-06-25 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Hochstufung | Needham | Hold → Buy |
| 2023-09-05 | Herabstufung | UBS | Buy → Neutral |
| 2023-08-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Eingeleitet | UBS | Buy |
| 2023-04-14 | Eingeleitet | Mizuho | Buy |
| 2023-01-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-20 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-09-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-08-15 | Herabstufung | CLSA | Buy → Outperform |
| 2022-08-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-01-31 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-28 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Hochstufung | CLSA | Outperform → Buy |
| 2022-01-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-10-22 | Hochstufung | CLSA | Underperform → Outperform |
| 2021-08-02 | Herabstufung | CLSA | Outperform → Sell |
| 2021-08-02 | Herabstufung | Needham | Buy → Hold |
| 2021-07-28 | Hochstufung | Jefferies | Underperform → Hold |
| 2021-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2021-06-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-06-22 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-06-22 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-06-21 | Bestätigt | Needham | Buy |
| 2021-06-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Hochstufung | CLSA | Sell → Outperform |
| 2021-05-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-16 | Hochstufung | Needham | Hold → Buy |
| 2020-11-02 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Eingeleitet | CLSA | Underperform |
| 2020-01-31 | Herabstufung | UBS | Buy → Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-22 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Hochstufung | UBS | Neutral → Buy |
| 2019-07-16 | Herabstufung | UBS | Buy → Neutral |
| 2019-05-06 | Hochstufung | UBS | Neutral → Buy |
| 2019-04-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Eingeleitet | Goldman | Buy |
Alle ansehen
Resmed Inc Aktie (RMD) Neueste Nachrichten
ResMed Inc. stock falls Friday, underperforms market - MSN
United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Purchases 7,020 Shares of ResMed Inc. $RMD - MarketBeat
Intech Investment Management LLC Boosts Stock Position in ResMed Inc. $RMD - MarketBeat
Eurizon Capital SGR S.p.A. Acquires Shares of 216,193 ResMed Inc. $RMD - MarketBeat
AdvisorShares Investments LLC Takes Position in ResMed Inc. $RMD - MarketBeat
Should you continue to hold Resmed stock in your portfolio? - MSN
RMD Stock Price, Quote & Chart | RESMED INC (NYSE:RMD) - ChartMill
ResMed Inc (RMD) Stock Down 6.3% -- Now Undervalued? GF Score: 9 - GuruFocus
ResMed (RMD) slides as shares hit a 52-week low amid renewed post-earnings scrutiny - Quiver Quantitative
ResMed stock hits 52-week low at $198.60 amid challenging year - Investing.com Nigeria
ResMed Inc. stock (US7611521078): shares ease while investors look to valuation metrics - AD HOC NEWS
Fideuram Asset Management Ireland dac Acquires New Stake in ResMed Inc. $RMD - MarketBeat
ResMed Inc. stock falls Thursday, underperforms market - MarketWatch
Legal & General Group Plc Increases Stock Holdings in ResMed Inc. $RMD - MarketBeat
Employees Retirement System of Texas Boosts Stock Holdings in ResMed Inc. $RMD - MarketBeat
Fisher Asset Management LLC Raises Stake in ResMed Inc. $RMD - MarketBeat
AlphaQuest LLC Sells 8,469 Shares of ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Shares Acquired by Allstate Corp - MarketBeat
Form 144: RMD (NYSE) affiliate lists 8,000 shares; insider sold 2,000 - Stock Titan
Jefferies Financial Group Inc. Cuts Stock Holdings in ResMed Inc. $RMD - MarketBeat
ResMed (RMD) is a Top-Ranked Growth Stock: Should You Buy? - Yahoo Finance
Tandem Investment Advisors Inc. Cuts Holdings in ResMed Inc. $RMD - MarketBeat
ResMed Inc. stock (US7611521078): sleep-apnea specialist in focus after latest earnings update - AD HOC NEWS
ResMed Stock Near 52-Week Low Despite 21% EPS Growth: Here’s What the GLP-1 Data Actually Shows - TIKR.com
Do Wall Street Analysts Like ResMed Stock? - Yahoo Finance
ResMed Inc. (RMD) Stock Analysis: Robust Growth Potential Amidst Healthcare Innovations - DirectorsTalk Interviews
Life Cycle Investment Partners Ltd Invests $31.23 Million in ResMed Inc. $RMD - MarketBeat
Catalyst Funds Management Pty Ltd Sells 8,400 Shares of ResMed Inc. $RMD - MarketBeat
ResMed Inc. (NYSE:RMD) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Cumberland Partners Ltd Purchases 8,000 Shares of ResMed Inc. $RMD - MarketBeat
Why ResMed Sleep Tech Push Is Turning Heads? - Kalkine Media
EMA backs first oral Wegovy weight-loss pill for EU - MSN
Thrivent Financial for Lutherans Buys 11,481 Shares of ResMed Inc. $RMD - MarketBeat
Is the options market predicting a spike in ResMed stock? - MSN
ResMed Inc stock (US75102W1036): sleep apnea specialist draws attention after latest options moves - AD HOC NEWS
How ResMed–Oura Wearable Sleep Data Partnership Could Reshape ResMed's (RMD) Clinical Ecosystem - Sahm
ResMed stock (US7611521078): sleep apnea specialist in focus after latest earnings - AD HOC NEWS
How Investors Are Reacting To ResMed (RMD) Linking Oura Ring Wearables To Clinical Sleep Care - Yahoo Finance
ResMed Inc. stock rises Wednesday, still underperforms market - MarketWatch
Is the Options Market Predicting a Spike in ResMed Stock? - Zacks Investment Research
ResMed stock (US7611521078): sleep apnea specialist in focus after latest quarterly results - AD HOC NEWS
ResMed (RMD) Valuation Check As Oura Sleep Health Collaboration Aims To Expand Sleep Apnea Care Access - Yahoo Finance
5,006 Shares in ResMed Inc. $RMD Acquired by North Dakota State Investment Board - MarketBeat
Resmed, Oura partner on sleep health education, care - MassDevice
Resmed (RMD) Teams Up with Oura to Enhance Sleep Health Educatio - GuruFocus
ResMed Rises After Partnership With Oura to Expand Sleep Health Education, Care Pathways - Moomoo
ResMed Inc. stock rises Tuesday, outperforms market - MarketWatch
Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference - Caledonian Record
ResMed Targets Circadian Data With New Wearable Trial: What Investors Should Watch - TipRanks
Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care - marketscreener.com
Oura Ring now links sleep changes to Resmed sleep resources - Stock Titan
Finanzdaten der Resmed Inc-Aktie (RMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.65%
0.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):